Hugel
Manufacturing · 51-200 Employees
View Company Info for Free
Overview
Website
www.hugel-aesthetics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Hugel
Hugel Aesthetics is a leading player in the South Korean aesthetics market, specializing in top-performing injectable products designed to help clients achieve their beauty goals. The company focuses on innovation, efficiency, and accessibility, aiming to make aesthetic treatments simple and inclusive for patients and practitioners worldwide. With a commitment to quality, Hugel's products have gained the trust of millions globally. The company is actively expanding its presence and offerings, including recent FDA approvals for its neurotoxin, Letybo, for treating glabellar lines.Explore more
Hugel Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Hugel your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if Hugel had a recent Job posting/layoffs
Check if Hugel has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Hugel launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Hugel is spiking on competitors!
Funding: Get notified immidiatlly once Hugel has new funding data
Hugel, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Hugel recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Hugel
Recommended Actions
Find VP level buyers at Hugel
Find 3 more new buyers
Compare Similar Companies to Hugel
Compare insights from companies similar to Hugel, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Hugel is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Hugel is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Hugel.
Hugel Tech Stack
A closer look at the technologies used by Hugel
See more technologies
Most Recent Scoops
Event
Product Marketing, Events, Search, Doctors / Physicians, Medical Research, Clinical Operations, Field Marketing, Healthcare Operations, Operations
Hiring Plans
Hugel has more open roles in Marketing than it has had at any time in the past 12 months. Areas of expertise include: Market Research, and Go-to-Market Strategy.
Hiring Plans
Open Position
Hiring Plans
Hugel has more open roles in Sales than it has had at any time in the past 12 months.
Hiring Plans
Left Company
Executive Move
Executive Moves, Left Company
Hugel News & Media
Croma Australia Pty Ltd, a subsidiary of Hugel Aesthetics, Receives TGA Approval in Australia for LETYBO (letibotulinumtoxinA) for the Treatment of Glabellar Lines
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Hugel America, Inc., (Hugel Aesthetics), today announced it received Therapeutic Goods Administration (TGA) approval for LETYBO (letibotulinumtoxinA) to treat moderate-to-severe glabellar (frown) lines in adults. "We are thrilled with the TGA’s approval of LETYBO. This is a major milestone for Croma Australia as we focus on becoming a top aesthetics brand in Australia,” stated James Hartman, President, Hugel Aesthetics. “We are excited to deliver qualityHugel Aesthetics Receives FDA Acceptance of BLA Resubmission for LetibotulinumtoxinA for Injection for Glabellar Lines
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Hugel America, Inc. (Hugel Aesthetics) announced today the acceptance of its Biologics License Application for letibotulinumtoxinA, by the U.S. Food and Drug Administration (“FDA”). The FDA considered the resubmission a Class 2 response and has assigned a April 6, 2023 action date per the Prescription Drug User Fee Act (PDUFA). Jim Hartman, President of Hugel Aesthetics, stated, “We have worked diligently to advance our regulatory submission of letibotuliHugel Aesthetics Resubmits Biologics License Application for LetibotulinumtoxinA for Injection for Glabellar Lines to the FDA
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Hugel America, Inc. (Hugel Aesthetics) announced today that it has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for letibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines. The resubmission follows the receipt of a Complete Response Letter (CRL) from the FDA in March 2022, which required additional data to complete the review of the BLA. Deficiencies cited by the FDA iHugel Aesthetics to Present Data from Phase 3 Clinical Trial At 2022 American Society of Dermatologic Surgery Annual Meeting
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Hugel America, Inc. (Hugel Aesthetics) announced today that the company will have an oral presentation at the American Society for Dermatologic Surgery (ASDS) annual meeting (Oct. 6-10, 2022 in Denver, CO) highlighting data from its phase 3 clinical trial, BLESS III, assessing the efficacy of letibotulinumtoxinA in improving the psychosocial health-related quality of life (QoL) of subjects with moderate to severe glabellar lines. “Hyperfunctional glabella
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Hugel
Sign Up For FreeTo access detailed company insights
Hugel Aesthetics is a leading player in the South Korean aesthetics market, specializing in top-performing injectable products designed to help clients achieve their beauty goals. The company focuses on innovation, efficiency, and accessibility, aiming to make aesthetic treatments simple and inclusive for patients and practitioners worldwide. With... Read More
